Newbury Pharmaceuticals AB (publ) reported earnings results for the full year ended August 31, 2023. For the full year, the company reported sales was SEK 10.27 million compared to SEK 5.52 million a year ago. Net loss was SEK 19.43 million compared to SEK 14.67 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 SEK | +8.81% |
|
+8.12% | +12.70% |
04-10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
02-22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.70% | 8.02M | |
-15.68% | 7.81B | |
+33.77% | 1.29B | |
-14.18% | 340M | |
+2.07% | 271M | |
+11.11% | 226M | |
-25.69% | 71.19M | |
+26.08% | 62.64M |
- Stock Market
- Equities
- NEWBRY Stock
- News Newbury Pharmaceuticals AB
- Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023